Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Methods of treating cancer with farnesyltransferase inhibitors

A technology of farnesyltransferase and inhibitor, applied in the field of cancer therapy, can solve the problem of different response and so on

Pending Publication Date: 2020-05-19
KURA ONCOLOGY
View PDF82 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, patients respond differently to FTI therapy
Therefore, there is a still unmet need for methods of predicting the response of subjects with cancer to FTI therapy or of selecting cancer patients for FTI therapy

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Methods of treating cancer with farnesyltransferase inhibitors
  • Methods of treating cancer with farnesyltransferase inhibitors
  • Methods of treating cancer with farnesyltransferase inhibitors

Examples

Experimental program
Comparison scheme
Effect test

Embodiment I

[0389] Neutropenia predicts clinical response to tipifarnib in MDS

[0390] A clinical study of tipifarnib (300mg bid (twice a day), 3 weeks on / 1 week off) was conducted in 82 high-risk MDS / CMML subjects. At study entry, 67 subjects were transfusion dependent (TD), where subjects who received one or several red blood cell (RBC) transfusions during the screening period through the first administration of tipifarnib were classified as TD. Eleven (16%) of the initial 67 TD subjects receiving tipifarnib were found to be converted to transfusion independence (TI), which persisted from day 55 to day 666.

[0391] Figure 1A A graph showing the results of a retrospective analysis of the trial results for these 67 transfusion-dependent MDS subjects is shown. Initially, 30 / 67 (45%) MDS subjects were classified as having moderate to severe neutrophils based on their absolute neutrophil count (ANC) 1,000 cells / μl blood. During the tipifarnib study, 9 / 30 (30%) MDS subjects with moderat...

Embodiment II

[0396] Bone marrow homing of myeloid cells as indicated by neutropenia and / or low blood blast counts predicts clinical benefit of tipifarnib in AML

[0397] Clinical studies with tipifarnib were conducted in newly diagnosed elderly patients with high-risk AML (CTEP-20, phase 2) and patients with relapsed and refractory AML (INT-17, phase 2). Patient selection in these studies was not based on genetic markers. Anecdotal evidence of single-agent activity of tipirfarnib has been reported. However, overall clinical activity across the patient population does not support registration of tipifarnib. Additionally, a contemporaneous Ph3 study (AML301, N=457) failed to identify increased Tipirfarnib efficacy (hazard ratio = 1.02, not significant). In AML301, the median OS for the overall study was 107 days for the tipifarnib arm and 109 days for the BSC arm.

[0398] Figure 2A Graph showing the amount of bone marrow blasts, blood blasts and WBCs observed in samples from elderly p...

Embodiment III

[0410] CXCL12 expression or CXCL12 / CXCR4 expression ratio predicts clinical benefit of tipifarnib in multiple hematological malignancies

[0411] In the CTEP20 study, 9 complete responses (CR) and 13 best responses for disease progression (PD) were observed in 34 pts with available BM gene expression data. CXCL12 expression alone or as a ratio of expression to its receptor CXCR4 predicted complete response to tipifarnib treatment (p=0.08, p=0.001) ( Figure 20A ). CXCL12 and CXCL12 / CXCR4 ratio also indicated 2 partial responses (PR) observed in 13 highly advanced relapsed / refractory PTCL patients with available GEP (p=0.009, p=0.0007) ( Figure 20B ). Four objective responses and one tumor lysis syndrome were reported in 17 tipifarnib-treated CMML subjects with available pretreatment BM gene expression data ( Figure 20C ). CXCL12 expression (p=0.07) and CXCL12 / CXCR4 ratio (p=0.03) predicted those events ( Figure 20C ). In the INT-17 study, only 3 CRs were reported amon...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
diameteraaaaaaaaaa
Login to View More

Abstract

The present invention relates to the field of cancer therapy. Specifically, provided are methods of treating cancer in a subject having clinical signs of bone marrow homing of myeloid cells, includingneutropenia, isolated neutropenia, a low percentage of peripheral blood blasts with or without a high percentage of bone marrow blasts, and / or a low ratio of peripheral blood blasts to bone marrow blasts, with a farnesyltransferase inhibitor (FTI) that include determining whether the subject is likely to be responsive to the FTI treatment based on hematological characteristics indicating bone marrow homing of myeloid cells.

Description

[0001] Cross References to Related Applications [0002] The present application claims U.S. Provisional Patent Application No. 62 / 542,202 filed on August 7, 2017; U.S. Provisional Patent Application No. 62 / 596,339 filed on December 8, 2017; U.S. Provisional Patent Application No. 62 / 596,339 filed on February 14, 2018 Patent Application 62 / 630,686; and U.S. Provisional Patent Application 62 / 646,292, filed March 21, 2018, each of which is incorporated herein by reference in its entirety in its entirety. technical field [0003] The present invention relates to the field of cancer therapy. In particular, provided herein are methods of treating cancer using farnesyltransferase inhibitors. Background technique [0004] In the clinical management of cancer patients, segmenting patient populations to improve treatment response rates is becoming increasingly valuable. Farnesyltransferase inhibitors (FTI) are used in cancers, such as peripheral T-cell lymphoma (peripheral T-cell l...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/4709A61K31/4725A61K39/395A61K45/00
CPCA61K31/4709A61P35/00A61P35/02A61K31/4704
Inventor 安东尼奥·瓜尔贝托
Owner KURA ONCOLOGY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com